Citable filing context

GEHC filing events and research context

Server-rendered

GEHC's research view summarizes recent SEC filing context, starting with mda_quarterly from Apr 29, 2026.

GEHC filing events and research context
FiledItemContext
Apr 29, 2026mda_quarterlyGE HealthCare reported total revenues of $5.13 billion for the first quarter of 2026, representing 7.4% reported growth and 2.9% organic growth. Performance was driven by strength in the Pharmaceutical Diagnostics (PDx), Imaging, and Advanced Visualization Solutions (AVS) segments, though the Patient Care Solutions (PCS) segment declined 6.5% due to the timing of installations. Regionally, the company saw double-digit growth in EMEA and the Rest of World, while the China market faced a 4.4% revenue decline amid increased local competition and volume-based procurement policies. Profitability faced significant headwinds, with operating income falling 18.2% to $515 million. Margins were compressed by 310 basis points, primarily due to cost inflation and the impact of incremental global tariffs, which negatively affected operating income by approximately $90 million. Additionally, the company incurred higher engineering costs for new product design follow-through. Despite these pressures, GE HealthCare maintains a solid liquidity position with $2.29 billion in cash and access to $3.5 billion in revolving credit facilities. Capital allocation remains active, highlighted by the $2.3 billion acquisition of Intelerad and $100 million in share repurchases. Management continues to monitor geopolitical instability and trade frictions, which remain key risks to supply chain stability and future financial performance.
Feb 4, 2026businessGE HealthCare is a global provider of medical technology, pharmaceutical diagnostics, and AI-enabled software, spun off from General Electric in January 2023. The company operates through four primary segments: Imaging, which includes Molecular Imaging, CT, MR, and X-ray; Advanced Visualization Solutions, focusing on specialized ultrasound and procedural guidance; Patient Care Solutions, covering patient monitoring, diagnostic cardiology, and life support; and Pharmaceutical Diagnostics, which produces contrast media and radiopharmaceuticals. Revenue is generated through equipment sales, consumables, and service contracts, with a notable historical trend of higher fourth-quarter results driven by customer spending patterns. The company leverages a workforce of 11,100 engineers to integrate AI and cloud solutions across its portfolio to enhance clinical workflows and precision care. Serving hospitals and researchers in over 160 countries, GE HealthCare faces intense competition from global peers such as Siemens Healthineers, Philips Healthcare, and United Imaging, as well as specialized pharmaceutical competitors like Bayer and Bracco. The business strategy emphasizes R&D and strategic acquisitions to maintain its competitive edge in diagnostic imaging and patient monitoring, while utilizing a "Heartbeat" lean business system to drive operational efficiency.
Feb 4, 2026mdaGE HealthCare reported 2025 total revenues of $20.6 billion, a 4.8% increase driven by strong performance in the Pharmaceutical Diagnostics (PDx) segment, which grew 15.6% following the Nihon Medi-Physics acquisition. Imaging and Advanced Visualization Solutions (AVS) also saw growth, while Patient Care Solutions (PCS) declined 1.2% due to weakness in Life Support Solutions. Regionally, growth in the U.S., Canada, and EMEA was offset by a 4.6% revenue decline in China, where Volume Based Procurement policies and local competition persist. Operating income rose 5.3% to $2.76 billion, though Adjusted EBIT decreased 1.8% to $3.16 billion. Financial results were materially pressured by global tariffs, which reduced 2025 operating income by approximately $245 million and cash flows by $285 million. The company continues to manage geopolitical risks in Russia and Ukraine, specifically regarding export licenses for spare parts. Liquidity remains stable with $4.5 billion in cash, though total debt increased to $10 billion. Strategic expansion continues with the acquisition of icometrix NV and a pending $2.3 billion cash agreement to acquire Intelerad.

Source: SEC EDGAR filing text and events; period Apr 29, 2026; filed Apr 29, 2026.

Continue research

Keep researching GEHC

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →